Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 36 entries
Sorted by: Best Match Show Resources per page
Management of Heparin-Induced Thrombocytopenia During Renal Replacement Therapy.

Hemodialysis international. International Symposium on Home Hemodialysis

Davenport A.
PMID: 28452439
Hemodial Int. 2001 Jan;5(1):81-85. doi: 10.1111/hdi.2001.5.1.81.

Awareness is increasing concerning the development of antibodies to heparin-platelet factor 4 complex in both regular hemodialysis patients and those treated with continuous forms of renal replacement therapy. Although the development of antibodies does not result in thrombocytopenia or...

Cite
Davenport A. Management of Heparin-Induced Thrombocytopenia During Renal Replacement Therapy. Hemodial Int. 2001;5(1):81-85doi: 10.1111/hdi.2001.5.1.81.
Davenport, A. (2001). Management of Heparin-Induced Thrombocytopenia During Renal Replacement Therapy. Hemodialysis international. International Symposium on Home Hemodialysis, 5(1), 81-85. https://doi.org/10.1111/hdi.2001.5.1.81
Davenport, Andrew. "Management of Heparin-Induced Thrombocytopenia During Renal Replacement Therapy." Hemodialysis international. International Symposium on Home Hemodialysis vol. 5,1 (2001): 81-85. doi: https://doi.org/10.1111/hdi.2001.5.1.81
Davenport A. Management of Heparin-Induced Thrombocytopenia During Renal Replacement Therapy. Hemodial Int. 2001 Jan;5(1):81-85. doi: 10.1111/hdi.2001.5.1.81. PMID: 28452439.
Copy Download .nbib Format: NLM
Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation.

Journal of vascular and interventional neurology

Feiz F, Sedghi R, Salehi A, Hatam N, Bahmei J, Borhani-Haghighi A.
PMID: 27403222
J Vasc Interv Neurol. 2016 Jun;9(1):35-41.

BACKGROUND: Anticoagulation with adjusted dose warfarin is a well-accepted treatment for the prevention of recurrent stroke in patients with atrial fibrillation. Meanwhile, using bridging therapy with heparin or heparinoids before warfarin for initiation of anticoagulation is a matter of...

Cite
Feiz F, Sedghi R, Salehi A, et al. Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation. J Vasc Interv Neurol. 2016;9(1):35-41
Feiz, F., Sedghi, R., Salehi, A., Hatam, N., Bahmei, J., & Borhani-Haghighi, A. (2016). Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation. Journal of vascular and interventional neurology, 9(1), 35-41.
Feiz, Farnia, et al. "Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation." Journal of vascular and interventional neurology vol. 9,1 (2016): 35-41.
Feiz F, Sedghi R, Salehi A, Hatam N, Bahmei J, Borhani-Haghighi A. Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation. J Vasc Interv Neurol. 2016 Jun;9(1):35-41. PMID: 27403222; PMCID: PMC4925764.
Copy Download .nbib Format: NLM
Interstitial cystitis: characterization and management of an enigmatic urologic syndrome.

Reviews in urology

Nickel JC.
PMID: 16985667
Rev Urol. 2002;4(3):112-21.

The enigmatic urologic condition known as interstitial cystitis has an estimated prevalence of 0.01% to 0.50% of the female population. Its etiology is unknown but may involve microbiologic, immunologic, mucosal, neurogenic, and/or other, as yet undefined, agents. There is...

Cite
Nickel JC. Interstitial cystitis: characterization and management of an enigmatic urologic syndrome. Rev Urol. 2002;4(3):112-21
Nickel, J. C. (2002). Interstitial cystitis: characterization and management of an enigmatic urologic syndrome. Reviews in urology, 4(3), 112-21.
Nickel, J Curtis. "Interstitial cystitis: characterization and management of an enigmatic urologic syndrome." Reviews in urology vol. 4,3 (2002): 112-21.
Nickel JC. Interstitial cystitis: characterization and management of an enigmatic urologic syndrome. Rev Urol. 2002;4(3):112-21. PMID: 16985667; PMCID: PMC1475982.
Copy Download .nbib Format: NLM
New treatments in acute ischemic stroke.

Current treatment options in neurology

Schneck MJ, Biller J.
PMID: 16221373
Curr Treat Options Neurol. 2005 Nov;7(6):499-511. doi: 10.1007/s11940-005-0050-y.

Since the advent of intravenous thrombolytic therapy with recombinant tissue plasminogen activator (tPA) for acute ischemic stroke, there has been a marked change in our management approach to patients with acute ischemic stroke. Although the major part of our...

Cite
Schneck MJ, Biller J. New treatments in acute ischemic stroke. Curr Treat Options Neurol. 2005;7(6):499-511doi: 10.1007/s11940-005-0050-y.
Schneck, M. J., & Biller, J. (2005). New treatments in acute ischemic stroke. Current treatment options in neurology, 7(6), 499-511. https://doi.org/10.1007/s11940-005-0050-y
Schneck, Michael J, and Biller, José. "New treatments in acute ischemic stroke." Current treatment options in neurology vol. 7,6 (2005): 499-511. doi: https://doi.org/10.1007/s11940-005-0050-y
Schneck MJ, Biller J. New treatments in acute ischemic stroke. Curr Treat Options Neurol. 2005 Nov;7(6):499-511. doi: 10.1007/s11940-005-0050-y. PMID: 16221373.
Copy Download .nbib Format: NLM
Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter.

Current treatment options in cardiovascular medicine

Bhave PD, Knight BP.
PMID: 23568665
Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):450-66. doi: 10.1007/s11936-013-0242-9.

OPINION STATEMENT: Anticoagulation is a key component of peri-procedural care for patients undergoing catheter ablation for atrial fibrillation (AF) and atrial flutter (AFL). The timing of discontinuation and re-initiation of anticoagulants in the peri-procedural time frame is an important...

Cite
Bhave PD, Knight BP. Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Curr Treat Options Cardiovasc Med. 2013;15(4):450-66doi: 10.1007/s11936-013-0242-9.
Bhave, P. D., & Knight, B. P. (2013). Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Current treatment options in cardiovascular medicine, 15(4), 450-66. https://doi.org/10.1007/s11936-013-0242-9
Bhave, Prashant D, and Knight, Bradley P. "Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter." Current treatment options in cardiovascular medicine vol. 15,4 (2013): 450-66. doi: https://doi.org/10.1007/s11936-013-0242-9
Bhave PD, Knight BP. Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter. Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):450-66. doi: 10.1007/s11936-013-0242-9. PMID: 23568665.
Copy Download .nbib Format: NLM
Novel anticoagulant use for venous thromboembolism: a 2013 update.

Current treatment options in cardiovascular medicine

Perez A, Merli GJ.
PMID: 23385736
Curr Treat Options Cardiovasc Med. 2013 Apr;15(2):164-72. doi: 10.1007/s11936-013-0230-0.

OPINION STATEMENT: Many pharmacologic options are available for prevention and treatment of venous thromboembolism (VTE). The anticoagulant selected may vary according the individual patient situation such as the acute versus chronic setting, renal function and indication for either VTE...

Cite
Perez A, Merli GJ. Novel anticoagulant use for venous thromboembolism: a 2013 update. Curr Treat Options Cardiovasc Med. 2013;15(2):164-72doi: 10.1007/s11936-013-0230-0.
Perez, A., & Merli, G. J. (2013). Novel anticoagulant use for venous thromboembolism: a 2013 update. Current treatment options in cardiovascular medicine, 15(2), 164-72. https://doi.org/10.1007/s11936-013-0230-0
Perez, Alejandro, and Merli, Geno J. "Novel anticoagulant use for venous thromboembolism: a 2013 update." Current treatment options in cardiovascular medicine vol. 15,2 (2013): 164-72. doi: https://doi.org/10.1007/s11936-013-0230-0
Perez A, Merli GJ. Novel anticoagulant use for venous thromboembolism: a 2013 update. Curr Treat Options Cardiovasc Med. 2013 Apr;15(2):164-72. doi: 10.1007/s11936-013-0230-0. PMID: 23385736.
Copy Download .nbib Format: NLM
Blood Targets of Adjuvant Drugs Against COVID19.

Journal of blood medicine

Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A.
PMID: 32694923
J Blood Med. 2020 Jul 02;11:237-241. doi: 10.2147/JBM.S256121. eCollection 2020.

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases...

Cite
Di Micco P, Di Micco G, Russo V, et al. Blood Targets of Adjuvant Drugs Against COVID19. J Blood Med. 2020;11:237-241doi: 10.2147/JBM.S256121.
Di Micco, P., Di Micco, G., Russo, V., Poggiano, M. R., Salzano, C., Bosevski, M., Imparato, M., Fontanella, L., & Fontanella, A. (2020). Blood Targets of Adjuvant Drugs Against COVID19. Journal of blood medicine, 11237-241. https://doi.org/10.2147/JBM.S256121
Di Micco, Pierpaolo, et al. "Blood Targets of Adjuvant Drugs Against COVID19." Journal of blood medicine vol. 11 (2020): 237-241. doi: https://doi.org/10.2147/JBM.S256121
Di Micco P, Di Micco G, Russo V, Poggiano MR, Salzano C, Bosevski M, Imparato M, Fontanella L, Fontanella A. Blood Targets of Adjuvant Drugs Against COVID19. J Blood Med. 2020 Jul 02;11:237-241. doi: 10.2147/JBM.S256121. eCollection 2020. PMID: 32694923; PMCID: PMC7338832.
Copy Download .nbib Format: NLM
Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing.

The Journal of pediatrics

Avila L, Amiri N, Yenson P, Khan S, Zavareh ZT, Chan AKC, Williams S, Brandão LR.
PMID: 32640269
J Pediatr. 2020 Nov;226:167-172.e2. doi: 10.1016/j.jpeds.2020.06.081. Epub 2020 Jul 05.

OBJECTIVES: To determine the applicability of the 4Ts score and the Heparin-Induced Thrombocytopenia (HIT) Expert Probability (HEP) score in children with suspected HIT and to estimate the number of children potentially at risk of HIT.STUDY DESIGN: We retrospectively estimated...

Cite
Avila L, Amiri N, Yenson P, et al. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020;226:167-172.e2doi: 10.1016/j.jpeds.2020.06.081.
Avila, L., Amiri, N., Yenson, P., Khan, S., Zavareh, Z. T., Chan, A. K. C., Williams, S., & Brandão, L. R. (2020). Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. The Journal of pediatrics, 226167-172.e2. https://doi.org/10.1016/j.jpeds.2020.06.081
Avila, Laura, et al. "Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing." The Journal of pediatrics vol. 226 (2020): 167-172.e2. doi: https://doi.org/10.1016/j.jpeds.2020.06.081
Avila L, Amiri N, Yenson P, Khan S, Zavareh ZT, Chan AKC, Williams S, Brandão LR. Heparin-Induced Thrombocytopenia in a Pediatric Population: Implications for Clinical Probability Scores and Testing. J Pediatr. 2020 Nov;226:167-172.e2. doi: 10.1016/j.jpeds.2020.06.081. Epub 2020 Jul 05. PMID: 32640269.
Copy Download .nbib Format: NLM
Neutrophil extracellular traps and thrombosis in COVID-19.

medRxiv : the preprint server for health sciences

Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, Woodard W, Lezak SP, Lugogo NL, Knight JS, Kanthi Y.
PMID: 32511553
medRxiv. 2020 May 05; doi: 10.1101/2020.04.30.20086736.

BACKGROUND: Early studies of patients with COVID-19 have demonstrated markedly dysregulated coagulation and a high risk of morbid arterial and venous thrombotic events. While elevated levels of blood neutrophils and neutrophil extracellular traps (NETs) have been described in patients...

Cite
Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv. 2020;doi: 10.1101/2020.04.30.20086736.
Zuo, Y., Zuo, M., Yalavarthi, S., Gockman, K., Madison, J. A., Shi, H., Woodard, W., Lezak, S. P., Lugogo, N. L., Knight, J. S., & Kanthi, Y. (2020). Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.04.30.20086736
Zuo, Yu, et al. "Neutrophil extracellular traps and thrombosis in COVID-19." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.04.30.20086736
Zuo Y, Zuo M, Yalavarthi S, Gockman K, Madison JA, Shi H, Woodard W, Lezak SP, Lugogo NL, Knight JS, Kanthi Y. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv. 2020 May 05; doi: 10.1101/2020.04.30.20086736. PMID: 32511553; PMCID: PMC7274234.
Copy Download .nbib Format: NLM
Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations.

International journal of nephrology and renovascular disease

Lutz J, Jurk K, Schinzel H.
PMID: 28652799
Int J Nephrol Renovasc Dis. 2017 Jun 12;10:135-143. doi: 10.2147/IJNRD.S105771. eCollection 2017.

Many patients with chronic kidney disease (CKD) receive anticoagulation or antiplatelet therapy due to atrial fibrillation, coronary artery disease, thromboembolic disease, or peripheral artery disease. The treatment usually includes vitamin K antagonists (VKAs) and/or platelet aggregation inhibitors. The direct...

Cite
Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017;10:135-143doi: 10.2147/IJNRD.S105771.
Lutz, J., Jurk, K., & Schinzel, H. (2017). Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. International journal of nephrology and renovascular disease, 10135-143. https://doi.org/10.2147/IJNRD.S105771
Lutz, Jens, et al. "Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations." International journal of nephrology and renovascular disease vol. 10 (2017): 135-143. doi: https://doi.org/10.2147/IJNRD.S105771
Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017 Jun 12;10:135-143. doi: 10.2147/IJNRD.S105771. eCollection 2017. PMID: 28652799; PMCID: PMC5473496.
Copy Download .nbib Format: NLM
Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies.

Home hemodialysis international. International Symposium on Daily Home Hemodialysis

Davenport A.
PMID: 28466522
Home Hemodial Int (1997). 1998 Jan;2(1):41-59. doi: 10.1111/hdi.1998.2.1.41.

Although continuous renal replacement therapy (CRRT) provides greater cardiovascular and cerebrovascular stability compared to standard intermittent hemodialysis and/ or hemofiltration, to provide adequate solute removal, the CRRT circuit must function continuously. Patients with acute renal failure are usually prothrombotic,...

Cite
Davenport A. Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies. Home Hemodial Int (1997). 1998;2(1):41-59doi: 10.1111/hdi.1998.2.1.41.
Davenport, A. (1998). Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies. Home hemodialysis international. International Symposium on Daily Home Hemodialysis, 2(1), 41-59. https://doi.org/10.1111/hdi.1998.2.1.41
Davenport, Andrew. "Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies." Home hemodialysis international. International Symposium on Daily Home Hemodialysis vol. 2,1 (1998): 41-59. doi: https://doi.org/10.1111/hdi.1998.2.1.41
Davenport A. Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies. Home Hemodial Int (1997). 1998 Jan;2(1):41-59. doi: 10.1111/hdi.1998.2.1.41. PMID: 28466522.
Copy Download .nbib Format: NLM
Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study.

Journal of blood medicine

Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A, Castaldo G, Agrusta F, Bellizzi A, Amitrano M, Iannuzzo M, Sacco C, Lodigiani C, Fontanella A, Di Micco P.
PMID: 33603528
J Blood Med. 2021 Feb 11;12:69-75. doi: 10.2147/JBM.S285214. eCollection 2021.

BACKGROUND: Since the outbreak of novel coronavirus SARS-CoV2 around the world, great attention has been paid to the effects of such antithrombotic drugs as heparinoids, because they have antiviral action in vitro and antithrombotic actions in vivo. We conducted...

Cite
Cardillo G, Viggiano GV, Russo V, et al. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. J Blood Med. 2021;12:69-75doi: 10.2147/JBM.S285214.
Cardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., Sacco, C., Lodigiani, C., Fontanella, A., Di Micco, P. (2021). Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. Journal of blood medicine, 1269-75. https://doi.org/10.2147/JBM.S285214
Cardillo, Giuseppe, et al. "Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study." Journal of blood medicine vol. 12 (2021): 69-75. doi: https://doi.org/10.2147/JBM.S285214
Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A, Castaldo G, Agrusta F, Bellizzi A, Amitrano M, Iannuzzo M, Sacco C, Lodigiani C, Fontanella A, Di Micco P. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. J Blood Med. 2021 Feb 11;12:69-75. doi: 10.2147/JBM.S285214. eCollection 2021. PMID: 33603528; PMCID: PMC7886238.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 36 entries